Shorts

Adam B. Murphy, MD, MBA, MSCI, urges thoughtful AI integration to prevent clinician burnout

Joshua Lang, MD, MS, on matching treatment intensity to tumor biology

Joshua Halpern, MD, on the advantages of mail-in semen analysis

EV/pembro approval: Translating the science into global care

Janelle Bunce, PA-C, discusses a holistic approach to testosterone deficiency care

Matthew Galsky, MD, on the changing role of cisplatin eligibility in MIBC

Joshua Halpern, MD, on what’s next in male fertility diagnostics

EV/pembro toxicity: What patients need to know upfront

The UroOnc Minute: Using physician data to improve patient outcomes

Debra L. Fromer, MD, highlights efficacy data on tebipenem pivoxil for cUTI

Beyond trial and error: The future of functional urology

How the BRIDGE trial may impact bladder cancer treatment

A new perioperative standard emerges for MIBC

Matthew Galsky, MD, explains the significance of perioperative EV/pembro in MIBC

From symptoms to systems: How functional urology evolved

First Assist: The evolving role of cystectomy in bladder cancer

Closing the gap: Urologists and female sexual health

Testosterone and prostate cancer risk: A balanced message

Beyond cisplatin eligibility: A new MIBC standard

Anatomy vs function: What reconstruction really means

The role of focal therapy in an evolving prostate cancer landscape

Michael Uy, MD on the impact of unmet social needs in kidney stone disease

Urocross: The case for a retrievable BPH device

Ravi Munver, MD, on AI-guided treatment planning with the HYDROS system

What urologists need to know before using Break Wave

Hans Arora, MD, PhD, on the most critical factor in surgical team performance

Why TRT Is no longer a blanket denial for cardiac risk

Patient selection for perioperative treatment in high-risk localized prostate cancer

Heat, plastic, and exposure: What patients should know

Vivian Wan, MD, on the value of mapping biopsies for CIS detection